浏览全部资源
扫码关注微信
中国人民解放军北部战区总医院新生儿科,沈阳 110016
Published:30 March 2023,
Received:18 August 2022,
Revised:04 February 2023,
扫 描 看 全 文
张世楠,魏兵,蔡明轩等.ADRB2基因调控区多态性对SABA治疗儿童哮喘急性发作疗效的影响 Δ[J].中国药房,2023,34(06):714-718.
ZHANG Shinan,WEI Bing,CAI Mingxuan,et al.Effects of ADRB2 gene regulatory region polymorphism on the efficacy of SABA in the treatment of acute asthma attack in children[J].ZHONGGUO YAOFANG,2023,34(06):714-718.
张世楠,魏兵,蔡明轩等.ADRB2基因调控区多态性对SABA治疗儿童哮喘急性发作疗效的影响 Δ[J].中国药房,2023,34(06):714-718. DOI: 10.6039/j.issn.1001-0408.2023.06.14.
ZHANG Shinan,WEI Bing,CAI Mingxuan,et al.Effects of ADRB2 gene regulatory region polymorphism on the efficacy of SABA in the treatment of acute asthma attack in children[J].ZHONGGUO YAOFANG,2023,34(06):714-718. DOI: 10.6039/j.issn.1001-0408.2023.06.14.
目的
2
探究
ADRB2
基因调控区多态性对短效β
2
受体激动剂(SABA)治疗儿童哮喘急性发作疗效的影响。
方法
2
选取2016年10月-2020年10月就诊于中国人民解放军北部战区总医院的急性轻中度发作且接受SABA治疗7 d的支气管哮喘患儿127例,检测其基因型分布,比较不同基因型患儿治疗后肺功能指标的改善情况和疗效,并考察基因多态性高阶交互作用对疗效的影响。
结果
2
127例患儿中,rs2895795位点TT、TA、AA型分别有80、44、3例,rs11168070位点CC、CG、GG型分别有93、32、2例,rs12654778位点GG、GA、AA型分别有41、64、22例,均符合Hardy-Weinberg平衡(
P
>0.05)。治疗后,rs2895795位点TA型患儿的最高呼气流量占预计值百分比(PEF%pred)、用力呼气75%肺活量时的瞬间流量占预计值百分比(FEF75%pred)改善率均显著低于TT型(
P
<0.05);rs11168070位点CG型患儿的PEF%pred、FEF75%pred改善率均显著低于CC型(
P
<0.05);rs12654778位点GA、AA型患儿的PEF%pred改善率均显著低于GG型(
P
<0.05)。各位点不同基因型患儿治疗前后呼出气一氧化氮差值比较,差异均无统计学意义(
P
>0.05)。rs2895795位点TT型患儿的显效比例是TA+AA型患儿的2.358倍(
P
<0.05),
ADRB2
基因多态性高阶交互作用对哮喘患儿的疗效没有明显影响(
P
>0.05)。
结论
2
支气管哮喘患儿
ADRB2
基因调控区多态性与SABA用于哮喘患儿急性发作的疗效相关,rs2895795、rs11168070、rs12654778位点野生型患儿的肺功能改善更明显,且rs2895795位点TT型患儿接受SABA治疗的效果更好。
OBJECTIVE
2
To explore the effects of
ADRB2
gene regulatory region polymorphism on the efficacy of short-acting beta 2 receptor agonists (SABA) in the treatment of acute asthma attack in children.
METHODS
2
A total of 127 children with acute mild to moderate bronchial asthma who received SABA treatment for 7 days in the General Hospital of Northern Theater Command from October 2016 to October 2020 were selected to detect their genotype distribution and compare the improvement of pulmonary functional indicators and curative effect among different genotypes. The effect of the high-order interaction of gene polymorphism on therapeutic effect was investigated.
RESULTS
2
Among 127 children, there were 80, 44 and 3 cases of TT, TA and AA types at locus rs2895795, 93, 32 and 2 cases of CC, CG and GG types at locus rs11168070, and 41, 64 and 22 cases of GG, GA and AA types at locus rs12654778, respectively, in accordance with Hardy-Weinberg equilibrium (
P
>0.05). After treatment, the improvement rate of the peak expiratory flow in percent predicted value (PEF%pred) and the improvement rate of the forced expiratory flow at 75% vital capacity in percent predicted value (FEF75%pred) in children with TA type were significantly lower than that of TT type at locus rs2895795 (
P
<0.05); the improvement rates of PEF%pred and FEF75%pred in children with CG type were significantly lower than that of CC type at locus rs11168070 (
P
<0.05); the improvement rates of PEF%pred in children with GA and AA type were significantly lower than that of GG type at locus rs12654778 (
P
<0.05). The differences in fractional exhaled nitric oxide before and after treatment were not statistically significant among different genotypes at each locus (
P
>0.05). The proportion of remarkable improvement of children with TT type at locus rs2895795 was 2.358 times that of children with TA+AA type (
P
<0.05), and there was no significant effect of higher-order interaction of
ADRB2
polymorphism on the efficacy in children with asthma (
P
>0.05).
CONCLUSIONS
2
Polymorphisms in the regulatory region of the
ADRB2
gene in children with bronchial asthma are associated with the efficacy of SABA in the treatment of acute asthma attack in children. At locus rs2895795, rs11168070 and rs12654778, the improvement of lung function of children with wild-type is more obvious, and the efficacy of SABA treatment on children with TT type is better at locus rs2895795.
哮喘急性发作ADRB2基因调控区多态性短效β2受体激动剂疗效儿童
ADRB2gene regulatory region polymorphismshort-acting beta 2 receptor agonistsefficacychildren
PAPI A,BRIGHTLING C,PEDERSEN S E,et al. Asthma[J]. Lancet,2018,391(10122):783-800.
DENLINGER L C,HEYMANN P,LUTTER R,et al. Exacerbation-prone asthma[J]. J Allergy Clin Immunol Pract,2020,8(2):474-482.
卜晓凡,赵京. β2受体激动剂及其在哮喘治疗中的应用[J]. 临床药物治疗杂志,2018,16(6):12-15.
KAMINSKY D A,CHAPMAN D G. Asthma and lung mechanics[J]. Compr Physiol,2020,10(3):975-1007.
SLOB E M A,VIJVERBERG S J H,PALMER C N A,et al. Pharmacogenetics of inhaled long-acting beta2-agonists in asthma:a systematic review[J]. Pediatr Allergy Immunol,2018,29(7):705-714.
VIJVERBERG S J H,FARZAN N,SLOB E M A,et al. Treatment response heterogeneity in asthma:the role of genetic variation[J]. Expert Rev Respir Med,2018,12(1):55-65.
KARIMI L,VIJVERBERG S J,ENGELKES M,et al. ADRB2 haplotypes and asthma exacerbations in children and young adults:an individual participant data meta-analysis[J]. Clin Exp Allergy,2021,51(9):1157-1171.
HIKINO K,KOBAYASHI S,OTA E,et al. A meta-analysis of the influence of ADRB2 genetic polymorphisms on albuterol(salbutamol)therapy in patients with asthma[J]. Br J Clin Pharmacol,2021,87(4):1708-1716.
蔡明轩,魏兵,廖世峨,等. ADRB2基因调控区多态性与儿童哮喘易感性的相关性研究[J]. 中国当代儿科杂志,2021,23(11):1132-1140.
中华医学会儿科学分会呼吸学组,《中华儿科杂志》编辑委员会. 儿童支气管哮喘诊断与防治指南:2016年版[J]. 中华儿科杂志,2016,54(3):167-181.
张惠琴,张静静,刘雨东,等. 肺功能检查及呼出气一氧化氮在儿童支气管哮喘规范化管理中的应用[J]. 中国当代儿科杂志,2017,19(4):419-424.
蔡亲武,杨子江,王昌乐. 布地奈德或丙酸倍氯米松联合特布他林治疗小儿轻中度哮喘急性发作的疗效和安全性比较[J]. 中国药房,2017,28(24):3368-3371.
TAYLOR D R. Pharmacogenetics of beta2-agonist drugs in asthma[J]. Clin Rev Allergy Immunol,2006,31(2/3):247-258.
SLOB E M,MAITLAND-VAN DER ZEE A H,KOPPELMAN G H,et al. Precision medicine in childhood asthma[J]. Curr Opin Allergy Clin Immunol,2019,19(2):141-147.
GARCÍA-MENAYA J M,CORDOBÉS-DURÁN C,GARCÍA-MARTÍN E,et al. Pharmacogenetic factors affecting asthma treatment response:potential implications for drug therapy[J]. Front Pharmacol,2019,10:520.
BERNSTEIN D I,LUMMUS Z L,KESAVALU B,et al. Genetic variants with gene regulatory effects are asso-ciated with diisocyanate-induced asthma[J]. J Allergy Clin Immunol,2018,142(3):959-969.
ANEAS I,DECKER D C,HOWARD C L,et al. Asthma-associated genetic variants induce IL33 differential expression through an enhancer-blocking regulatory region[J]. Nat Commun,2021,12(1):6115.
HAWE J S,WILSON R,SCHMID K T,et al. Genetic variation influencing DNA methylation provides insights into molecular mechanisms regulating genomic function[J]. Nat Genet,2022,54(1):18-29.
NEVILLE M D C,CHOI J,LIEBERMAN J,et al. Identification of deleterious and regulatory genomic variations in known asthma loci[J]. Respir Res,2018,19(1):248.
POSTMA D S,BRIGHTLING C,BALDI S,et al. Explo-ring the relevance and extent of small airways dysfunction in asthma(ATLANTIS):baseline data from a prospective cohort study[J]. Lancet Respir Med,2019,7(5):402-416.
QIN R,AN J,XIE J,et al. FEF25-75% is a more sensitive measure reflecting airway dysfunction in patients with asthma:a comparison study using FEF25-75% and FEV1%[J]. J Allergy Clin Immunol Pract,2021,9(10):3649-3659.e6.
EKE GUNGOR H,SAHINER U M,ALTUNER TORUN Y. Spirometry in children with asthma and/or allergic rhinitis:comparison of FEF25-75% with the standard measures[J]. Minerva Pediatr,2019,71(2):103-109.
MILLER D,VAIDYA S,JAUERNIG J,et al. Lung function,pharmacokinetics,and tolerability of inhaled indacaterol maleate and acetate in asthma patients[J]. Respir Res,2020,21(1):248.
LIU Y,HUANG K,WANG Y H,et al. Integration of SNP disease association,eQTL,and enrichment analyses to identify risk SNPs and susceptibility genes in chronic obs-tructive pulmonary disease[J]. Biomed Res Int,2020,2020:3854196.
KELLY R S,CHAWES B L,BLIGHE K,et al. An integrative transcriptomic and metabolomic study of lung function in children with asthma[J]. Chest,2018,154(2):335-348.
LI J X,FU W P,ZHANG J,et al. A functional SNP upstream of the ADRB2 gene is associated with COPD[J]. Int J Chron Obstruct Pulmon Dis,2018,13:917-925.
0
Views
2
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution